Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| CID16020046 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. |  |
| CID16020046 | CID16020046 is a selective GPR55 inverse agonist. CID16020046 is a G protein-coupled receptor that is weakly activated by some cannabinoids at nM concentrations. CID16020046 has been shown to block GPR55-mediated endothelial wound healing and reverse LPI-inhibited platelet aggregation. Uses: Designed for use in research and industrial production. Additional or Alternative Names: CID16020046; CID-16020046; CID 16020046. Product Category: Agonists. Appearance: Solid powder. CAS No. 834903-43-4. Molecular formula: C25H19N3O4. Mole weight: 425.44. Purity: >98%. IUPACName: 4-[4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1,4-dihydropyrrolo[3,4-d]pyrazol-5-yl]benzoic acid. Canonical SMILES: O=C(O)C1=CC=C(N(C2=O)C(C3=CC=CC(O)=C3)C4=C2NN=C4C5=CC=C(C)C=C5)C=C1. Product ID: ACM834903434. Alfa Chemistry ISO 9001:2015 Certified. |  |
| GPR55 Receptor Antagonist, CID16020046 (4-[4-(3-Hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H-pyrrolo[3,4-c]pyrazol-5-yl]benzoic Acid) | A selective antagonist of G protein-coupled receptor 55 (GPR55) that blocks lipid L-a-lysophosphatidyl inositol (LPI)-induced GPR55 activation (IC50 = 1uM) and downstream effects in HEK293 cells. Also shown to block the agonistic effect of LPI on GPR55- expressing yeast cells (~10uM). Inhibits LPI-induced Ca2+ mobilization and ERK1/2 phosphorylation in HEK-GPR55 and HEK-CB1 cells. However, it does not affect basal Ca2+ mobilization and ERK1/2 activity. Blocks the GPR55-mediated NFAT and NF-kB activation and their nuclear translocation in HEK-GPR55 cells. Diminishes LPI-induced wound healing in GPR55-expressing primary human lung microvascular endothelial cells and reverses LPI-inhibited platelet aggregation (~10uM). Also reported to inhibit the activity of phosphodiesterases PDE3A and PDE4B (pIC50 = 5 and 4.8, respectively). Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. Molecular Formula: C??H??N?O?. US Biological Life Sciences. |  Worldwide |
| CID 16020046 | CID 16020046 is a potent and selective GPR55(LPI receptor) antagonist, which inhibitsGPR55 constitutive activity. It reduced LPI-induced wound healing in primary human lung microvascular endothelial cells and reversed LPI-inhibited platelet aggregation. Synonyms: CID16020046; CID-16020046; CID 16020046. Grades: >98%. CAS No. 834903-43-4. Molecular formula: C25H19N3O4. Mole weight: 425.44. |  |
Our database is helping our users find suppliers everyday.
